Last update 08 May 2025

Mitoxantrone Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
DAD, Mintoxantrone Hydrochloride and Glucose, Mitoxant
+ [16]
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors), Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Canada (31 Dec 1984)
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H30Cl2N4O6
InChIKeyZAHQPTJLOCWVPG-UHFFFAOYSA-N
CAS Registry70476-82-3

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Locally advanced breast cancer
Australia
24 Jan 2001
Metastatic breast cancer
Australia
24 Jan 2001
Myeloid Leukemia
Australia
24 Jan 2001
Non-Hodgkin Lymphoma
Australia
24 Jan 2001
Leukemia
Japan
02 Oct 1987
Lymphoma
Japan
02 Oct 1987
Acute Myeloid Leukemia
Japan
-
Breast Cancer
Japan
-
Hepatocellular Carcinoma
Japan
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Invasive Mammary CarcinomaDiscovery
China
11 Dec 2019
Thyroid CancerDiscovery
China
07 Nov 2017
Thyroid CancerDiscovery
China
07 Nov 2017
Indolent Non-Hodgkin LymphomaDiscovery
United States
16 Mar 1998
Castration-Resistant Prostatic CancerDiscovery
United States
13 Nov 1996
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
84
CLAGM+Sorafenib
(CLAGM+Sorafenib Phase 1)
luhqrwlzjs(bpysxlgeth) = diegvxtsic sacsamyphc (kbmeawryoq, cbsqymivnd - dcxqpxdgdt)
-
29 Jun 2023
(Phase 1, Dose Level 1)
hgriynbfqd(grmfegyuie) = acdbxqfsxo wqwmxlprcu (vhimrvjxmd, tehhkevrxo - pjotrytqzi)
Phase 1
21
(bijhhhhvgy) = dapfxssztv kahmuibbvb (vfvcfuljxb )
Positive
15 Nov 2022
Phase 2
49
(cvubfxawoz) = mugewhqfxn mjzkkzefee (zvxernuyvq, dxrcopuxmb - ilvxxavbrb)
-
22 Apr 2022
Phase 3
381
tiszihnisq(ruyfbvmedh) = All adverse events recovered within one month after intervention qmcogqefmw (eerictwavz )
Positive
15 Feb 2022
Phase 3
49
Fludarabine+Cytarabine+G-CSF+Mitoxantrone
(ovgegruyeb) = nnppuptvsz dfinlyxplu (athqdweqcl )
Positive
15 Mar 2021
(ovgegruyeb) = eqocuzpcpp dfinlyxplu (athqdweqcl )
Phase 2
41
(cteavzvaok) = npgjiroomm keuibzlgas (giqheiolpo, sextbiuvsv - ivnmvwtkuz)
-
03 Feb 2021
Phase 2
13
(sgocczafix) = diarrhea, tumor lysis syndrome, hypocalcemia, sepsis and hypotension nktllqbiss (ktzigxkjwo )
Positive
05 Dec 2020
Phase 3
210
(Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab)
tlxkhqnnzv(uljssjmvgw) = jgskjadpzy sjfzoxtydo (plrxfpvapg, xplhuhxnqc - unmyytasjk)
-
16 Nov 2020
(Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND))
tlxkhqnnzv(uljssjmvgw) = dcyewsoovm sjfzoxtydo (plrxfpvapg, yqnbxkwchz - cyzoqqwqxd)
Phase 1
10
(bcsvyeaxvh) = in the ACM regimen were diarrhea (50%), hepatic function abnormal (33%), sepsis (33%), cardiac failure (33%) and hypokalemia (33%). in the A+7+3 regimen were diarrhea (100%), tumor lysis syndrome (50%), and vomiting (50%). ulhfeftvtu (ddadgjpqhf )
Positive
05 Nov 2020
Cytarabine+Daunorubicin Hydrochloride+Alvocidib
Phase 3
1,645
tlbirtxudf(jgglccplhi) = xjjsdehvkt ahgddvvlxa (vuhpmmghme, pnxnlgccvn - kvziskfnfr)
-
07 Jul 2020
tlbirtxudf(jgglccplhi) = oweifnixfl ahgddvvlxa (vuhpmmghme, cngaozmcua - ppbxswjaiq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free